Levomethadon G.L. Pharma

Levomethadone hydrochloride, the active ingredient in Levomethadon G.L. Pharma, is a synthetic opioid presented as an oral formulation for oral use. It is employed in pain management and opioid dependence treatment for adult patients. GNH USA supplies Levomethadon G.L. Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Levomethadon G.L. Pharma is a synthetic opioid that acts on the mu‑opioid receptor pathway to relieve pain and support opioid substitution therapy. - Acute pain: provides rapid analgesia for severe short‑term pain episodes. - Chronic pain: offers sustained relief for long‑term conditions such as cancer‑related pain. - Opioid dependence treatment: used in maintenance programs to reduce withdrawal symptoms and cravings.

Levomethadon G.L. Pharma may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Constipation: reduced bowel motility. - Drowsiness: increased sleepiness or fatigue. - Dry mouth: reduced salivation.

Serious or Rare Side Effects: - Respiratory depression: slowed or shallow breathing. - QT interval prolongation: potential cardiac rhythm disturbances. - Severe hypotension: marked drop in blood pressure.

Before initiating therapy with Levomethadon G.L. Pharma, clinicians should consider several safety measures. - Respiratory assessment: evaluate baseline breathing function. - Liver function: monitor hepatic enzymes regularly. - Dependence risk: assess patient history for substance misuse. - CNS depression: avoid concurrent use with other depressants. - Renal impairment: adjust use in patients with reduced kidney function. - Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Levomethadon G.L. Pharma can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Central nervous system depressants (e.g., benzodiazepines, barbiturates): may cause profound sedation or respiratory depression. - Monoamine oxidase inhibitors (MAOIs) within 14 days: risk of severe hypertension or serotonin syndrome.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may increase levomethadone plasma levels. - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce therapeutic effect. - Serotonergic agents (e.g., SSRIs, tramadol): potential for serotonin syndrome.